Targeted protein degradation offers the potential to solve difficult-to-treat diseases, but the first wave of these experimental therapies only targets disease-causing proteins in cells.Eli Lilly sees technology Lycian therapy, To solve the problem of extracellular protein, as a next-generation protein degradation therapy, it paid 35 million US dollars to start-up companies to start a research alliance.
Partnerships Announce Up to five drugs are covered on Wednesday. The two companies will use Lycia’s technology to discover them, and Eli Lilly will bear the cost of preclinical and clinical development. The deal provides the Indianapolis pharmaceutical giant with an exclusive global license to commercialize these drugs if they are approved. Lycia, headquartered in southern San Francisco, can receive more than $1.6 billion in milestone payments related to the progress of these drugs, as well as royalties from the sale of commercialized products under the agreement.
Protein degradation drugs use the cell’s built-in system to process old or damaged proteins and use it to remove disease-causing proteins. These proteins are directed to the proteasome, like a cellular trash can. The “targeting” part of targeted protein degradation means that small molecules attach to the protein in question, grab an enzyme, and label the protein for disposal. Companies that develop protein-degrading drugs based on this method that occurs in cells include Kymera Therapeutics and Arvinas.Earlier this month, in New Haven, Connecticut, Arvinas and Pfizer have reached a $1 billion alliance, which will develop and possibly commercialize the biotechnology’s protein-degrading breast cancer drugs.
The protein that causes disease can also be found outside the cell. These extracellular proteins are the target of Lycia’s technology, which is called LYTAC, which is an abbreviation for lysosomal targeted chimera. LYTAC drugs include antibodies and small molecules that can direct disease-causing proteins to different processing systems called lysosomes. In a statement, Eli Lilly’s vice president of immunology, Ajay Nirula, stated that his company believes that Lycia technology can develop targeted drugs that were previously infeasible. He added that potential disease areas for collaboration include immunology and pain.
Other drug developers aiming to use lysosomes to treat diseases include PAQ Therapeutics, recently received $30 million in Series A financing Of funds. A biotechnology company based in Cambridge, Massachusetts is developing small molecule drugs, and its first disease target is hereditary neurodegenerative diseases.
Lycia has not disclosed its internal drug pipeline. The alliance with Eli Lilly is the first alliance announced by this young company.start up roll out Last year, it received a US$50 million Series A financing from Versant Ventures. Lycia’s science originated in the laboratory of Carolyn Bertozzi, a professor of chemistry at Stanford University. In 2019, Bertozzi is one of the authors of a book. Preprint Describes how to use transmembrane glycoproteins to capture extracellular proteins and drag them into the cell. These proteins are directed to the lysosome for destruction.
Since 2017, Bertozzi has also served as an independent director of Lilly’s board of directors. In terms of cooperation and licensing agreements, Lilly Announce Bertozzi has resigned from the board of directors.
Photo: Konrad Fiedler/Bloomberg via Getty Images
